Rezolute, Inc. (RZLT) Stock Ticker
RZLT right now
Market factors today
Unlock the full RZLT picture
About Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
RZLT stock facts
| Ticker symbol | RZLT |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $375.5M |
| CEO | Nevan Charles Elam |
| Employees | 58 |
| Headquarters | Redwood City, CA, US |
| IPO date | 2013-01-14 |
| Website | www.rezolutebio.com |
What you can see for RZLT on Tickr
Live RZLT price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the RZLT report.
Rankings
FAQ
What is the ticker symbol for Rezolute, Inc.?
The ticker symbol for Rezolute, Inc. is RZLT, listed on the NASDAQ.
What is RZLT?
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for…